StoxRubicon Research vs Granules India: share price & financials comparison
NSE: RUBICON vs GRANULES · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Rubicon Research vs Granules India at a glance
Rubicon Research (RUBICON) has a market capitalisation of ₹27,466 Cr, against ₹21,813 Cr for Granules India (GRANULES). Over the past year Rubicon Research has returned +176.3%, compared with +40.0% for Granules India. On valuation, Granules India trades at a lower P/E of 30.6 versus 84.6. Rubicon Research earns a higher return on equity (22.9% vs 10.9%). Rubicon Research comes out ahead on profitability, growth, momentum and technicals. Granules India comes out ahead on size, valuation and financial health. Across the scored metrics below, Rubicon Research leads on 9 and Granules India on 5. On StoxGud's 10-point checklist, Rubicon Research scores 8/10 and Granules India scores 8/10.
| Metric | Rubicon Research | Granules India |
|---|---|---|
| Size | ||
| Market cap | ₹27,466 Cr | ₹21,813 Cr |
| Revenue (latest FY) | ₹1,754 Cr | ₹5,366 Cr |
| Net profit (latest FY) | ₹247 Cr | ₹595 Cr |
| Valuation | ||
| P/E | 84.6 | 30.6 |
| P/B | 19.39 | 3.32 |
| Dividend yield | 0.00% | 0.17% |
| Profitability | ||
| Return on equity | 22.9% | 10.9% |
| Net profit margin | 15.5% | 12.1% |
| Operating margin | 23.8% | 22.7% |
| Growth | ||
| Revenue growth (YoY) | +39.9% | +20.3% |
| Net profit growth (YoY) | +68.0% | +39.2% |
| Revenue CAGR (multi-year) | — | +10.6% |
| Financial health | ||
| Debt to equity | 0.28 | 0.09 |
| Momentum | ||
| 1-month return | +5.3% | -5.4% |
| 1-year return | +176.3% | +40.0% |
| 3-year CAGR | — | +31.6% |
| 5-year CAGR | — | +20.2% |
| 10-year CAGR | — | +21.4% |
| Distance from 52W high | -10.8% | -12.1% |
| Technicals | ||
| RSI (14) | 65 | 42 |
| Price vs 200-day avg | +35.2% | +7.5% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Rubicon Research | Granules India |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 8/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Rubicon Research or Granules India?
Rubicon Research has a market cap of ₹27,466 Cr and Granules India has a market cap of ₹21,813 Cr as of 06 Nov 2026.
Which has a lower P/E, Rubicon Research or Granules India?
Granules India has the lower P/E: Rubicon Research trades at 84.6 and Granules India at 30.6.
Which gave better returns in the last year, Rubicon Research or Granules India?
Rubicon Research did better: Rubicon Research returned +176.3% and Granules India returned +40.0% over one year.
Is Rubicon Research or Granules India a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Rubicon Research scores 8/10 and Granules India scores 8/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.